I have been banging the drum for Cytodyn to develop into its own full fledged pharmaceutical company since I first bought shares. Before we need talent we need revenue. Given the near term upward trajectory of the share price 25 million shares doled out over the next year is excessive. Once we are at substantial revenue let the company buy back shares to use as compensation (as long as the compensation is reasonable) and I won't give a hoot.